Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.
|Title||Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.|
|Publication Type||Journal Article|
|Year of Publication||2018|
|Authors||Henriques ADallanora, Benedet ALessa, Camargos EFrancisco, Rosa-Neto P, Nóbrega OToledo|
|Date Published||2018 Jan 04|
There is increasing evidence that a number of potentially informative biomarkers for Alzheimer disease (AD) can improve the accuracy of diagnosing this form of dementia, especially when used as a panel of diagnostic assays and interpreted in the context of neuroimaging and clinical data. Moreover, by combining the power of CSF biomarkers with neuroimaging techniques to visualize Aβ deposits (or neurodegenerative lesions), it might be possible to better identify individuals at greatest risk for developing MCI and converting to AD. The objective of this article was to review recent progress in selected imaging and chemical biomarkers for prediction, early diagnosis and progression of AD. We present our view point of a scenario that places CSF and imaging markers on the verge of general utility based on accuracy levels that already match (or even surpass) current clinical precision.
|Alternate Journal||Exp. Gerontol.|
|Grant List||P41 EB015904 / EB / NIBIB NIH HHS / United States|